Steve Abbott brings a unique background in new business creation and traditional analytical process to the art of entrepreneurship. His ability to be inventive yet critical drives his evaluation model for potential business success.Steve graduated Magna Cum Laude from Cal Poly San Luis Obispo with a degree in Mathematics. He applied those skills to the insurance industry, specifically actuarial science. He earned the accreditation as an Associate of the Society of Actuaries and played an integral role in forming Specialty Insurance Service in the mid-80s. Steve transitioned from the CTO role to CEO and Partner by 1990 and he led the company through a round of venture financing and structured a successful exit in 1998.With the company that acquire his, Steve operated in various capacities, from business unit president to divisional CTO, for a division of a multi-billion dollar public holding company made up of over 100 operating units. Here he was responsible for growing business unit revenue and in developing operational strategy. He also participated as a part of due diligence teams in acquisitions.In 2003 he earned his EMBA from The Peter Drucker School of Management at the Claremont Graduate University. In 2004, Steve started an independent consulting firm specializing in M&A transactions for high-value closely held companies. The firm also specialized in mentoring and coaching promising entrepreneurs. During this time, he was a member of the Tech Coast Angels as well.In early 2009, Steve was part of the executive team that designed the initial underpinnings of ieCrowd. Steve is also an adjunct professor teaching courses in entrepreneurship at local universities.
Michael A. Alvarez
Michael A. Alvarez is Executive Director for the MD Anderson Center for Professional Development and Entrepreneurship, which provides education and training in these areas for clinicians and researchers, and engages externally with organizations across multiple sectors to facilitate the translation of knowledge, technologies, and expertise. Prior to this role, he founded and directed the Stanford School of Medicine Career Center, establishing relationships on behalf of the University, assisting and advising start-up companies, and developing innovative curricula to support the professional advancement of physicians and biomedical scientists. Throughout more than 20 years, his professional experience spans both business and academic settings, including coaching and advising at Boston College, management consulting as part of Accenture's NYC practice, founding and directing the UCSF Center for Career & Professional Development - serving all schools and disciplines - and providing independent consultation to life science companies in the areas of business strategy and organizational design. He is widely sought for input and expert opinion on labor market trends, technology commercialization, and medical science training, and has written, reviewed, and published many articles on these topics in key venues. Michael holds bachelor's and master's degrees from Boston College, a certificate in Intellectual Property Management from the University of Washington, and studied business at IESE in Barcelona, Spain. He is an Emeritus Chair of the Bay Bio Institute, supports bio-entrepreneurship as an advisor to early stage companies, and participates actively on bioscience committees and boards both regionally and nationally.
Curt Anderson has been a practicing industrial designer for 38 years. He holds a BS in Industrial Design from San Jose State University. Prior to founding Compass Product Design in 1989, Curt managed the Industrial Design and Graphic Design Group for Xerox's Office Products Division, a $2B division that manufactured facsimile machines, desktop copiers and electronic typewriters. Before Xerox, Curt was a designer at Tektronix, a test and measurement equipment company. In his career, Curt's designs have won awards in the US, Japan and Europe. Outside the office, he enjoys home remodeling projects, serving on volunteer boards and the pursuit of a better golf swing.
Bill Browne is Director of Workforce and Economic Development at Manex Consulting and has over 34 years of extensive manufacturing experience and expertise in general management, manufacturing operations, quality systems, engineering, product development and continuous improvement initiatives, including Lean Manufacturing and Six Sigma. Prior to joining Manex, Mr. Browne was General Manager at Triangle Coatings, Inc. where he was responsible for managing two manufacturing operations. During his tenure, he led the organization to achieve a 20% improvement in productivity. Previously, Mr. Browne held executive management positions with a number of organizations including Morgan Crucible, Consolidated Container Company and Mattel, Inc., where he was instrumental in driving cultural transformations that enhanced profitability, productivity and efficiency. Under his leadership at Mattel Toys Hong Kong, the operations doubled production without adding resources through the implementation of Just-In-Time manufacturing techniques. During his work with General Motors, he developed the process for the Vacuum Insertion of Engine Pistons, resulting in a pre-patent research disclosure. Mr. Browne holds an MBA with high honors from the University of Detroit, and a BS in Engineering Arts (a combination of Engineering and General Business) from Michigan State University.
The Sanofi External Science & Partnering organization is globally distributed in the major hubs of innovation and is charged with cultivating geographical ecosystems to uncover external innovation opportunities of interest to the global therapeutic areas to build their pipelines through external innovation. Sylvaine Cases is heading External Science & partnering for Sanofi in Western US and Canada. In this geography, she is responsible for cultivating relationships and bringing forward innovative partnering and collaboration opportunities from academic institutions, biotech companies, venture investment groups, and non-profit-organizations. Prior to joining Sanofi, Sylvaine has been working for 16 years in the San Francisco Bay area in academia and biotechnology and her experience covers basic and pre-clinical research and development in oncology and metabolic disorders. She held an academic appointment at the Gladstone Institutes and most recently the positions of Sr Group Leader at Sylvaine Cases received a MS in biochemistry from the French engineering school AgroParisTech in Paris, and a Ph.D. in Molecular Oncology from the University of Paris 7. She completed post-doctoral studies at the Gladstone Institutes/UCSF.
Aaron Castillo is a Production Manager at Penumbra Inc., a privately held medical device company treating stroke and vascular disease. Aaron has comprehensive experience in new product development, continuous improvement, and leadership development within the medical device industry.
Kevin Christopher is a Business Development Executive for Lawrence Livermore National Lab. His responsibilities there include building industrial research collaborations with a biomedical focus and managing an intellectual asset portfolio that includes biodefense, bioinformatics, food safety, imaging, neural implant, pharmaceutical, point-of-care diagnostic, and tissue engineering technologies. Kevin has previously served as a commercialization analyst for NIH and NSF SBIR programs, and as a startup advisor within the Small Business Administration's pilot Entrepreneurial Mentor Corps. He currently volunteers with regional business competitions such as OneStart, and civically as an economic development advisor for the City of Emeryville.
As the UC Berkeley Office of Technology Licensing's Director of Innovation Ecosystem Development, Mike drives initiatives, agreements and relationships that catalyze the commercialization of UC Berkeley innovations, and support the funding of campus research (that leads to innovations). In this role, Mike has worked with over 100 startups, and he has spearheaded the licensing of innovations in numerous areas including biofuels, photovoltaics, medical devices, wireless sensors, semiconductors, software, nano technology and biomimetic inventions. Mike's ecosystem initiatives include co-founding the Berkeley Startup Cluster, and the QB3 East Bay Innovation Center — a wet lab startup incubator for bioscience companies in West Berkeley. Mike conceived, co-championed and was the founding director (part-time) of the award winning Berkeley Skydeck — an information technology-oriented startup accelerator in Downtown Berkeley. Mike also has been on the steering committees for the East Bay Green Corridor, and UC Berkeley's Cleantech-to-Market program. Prior to his leadership on the commercialization of innovations at UC Berkeley, Mike held board, executive, product management, marketing, business development and engineering positions at high tech companies including HP, Sun, Mips, Silicon Graphics, Netpulse and Peak Democracy. Mike has co-founded two technology-based companies, and he has MBA and engineering degrees from Harvard and Tufts.
Justin Elstrott, PhD works as a Scientific Manager with Dr. Robby Weimer in the Biomedical Imaging Group at Genentech, where he uses in-vivo imaging and electrophysiology to study diseases such as Alzheimer's and cancer in preclinical animal models. He received his PhD in Computational Neuroscience from UC San Diego in 2009 researching retinal development in the labs of Prof. Marla Feller and Prof. EJ Chichilnisky. As a postdoc in the lab of Prof. Daniel Feldman at UC Berkley, he studied sensory cortex using electrophysiology and imaging. While a postdoc, he co-founded the Postdoc Industry Exploration Program and the Berkeley Postdoc Entrepreneur Program.
Holly J. Falk-Krzesinski, PhD, is the Vice President for Global Academic & Research Relations for Elsevier where she is focused on how insight from data and analytics guide strategic planning for the research enterprise. Dr. Falk-Krzesinski’s engagement activities emphasize building new relationships and strategic alliances around important issues for research and research training, such as those related to: research analytics & strategic planning; economic development; early career researcher development; scholarly communication & open access/open data; research & faculty information management; expertise discovery & collaboration; research metrics & impact. Dr. Falk-Krzesinski is also involved in broadly promoting women in STEM fields and serves on the Business Steering Group and as a Board-alternate for ORCID.
Graham Fleming is Vice Chancellor for Research and Professor of Chemistry at the University of California, Berkeley. As Vice Chancellor for Research, Fleming has overall responsibility for the University of California, Berkeley research endeavor and exercises primary leadership in research policy, planning and administration for the Berkeley campus which includes relations between the university and industry, research compliance, research communications and research support for the Berkeley campus. His administrative portfolio includes management of forty campus research units, twelve research museums and remote field stations, and research administration offices including the Office of Research Administration and Compliance, Office of Intellectual Property & Industry Research Alliances (IPIRA), Research Enterprise Services, and the Office of Lab Animal Care.
Eric Giegerich is Director of UC Berkeley's Industry Alliances Office, which serves to facilitate industry-university research collaboration. Besides one-to-one relationships between a company and UC Berkeley, the Industry Alliances Office facilitates multi-party research alliances with industry partners to help advance an area of research. Prior to UC Berkeley, Eric was in technology licensing at the Buck Institute for Age Research, focused on the basic biology of aging and neurodegenerative diseases.
Jennifer is based in San Francisco and is responsible for the National Biotechnology and Diagnostics practice. Jennifer joined Silicon Valley Bank after seven years at Pfizer, where she served as a Director on Pfizer's Venture Capital team and a Senior Manager in the Portfolio and Decision Analysis group. While a consultant at Bain & Company in London, Jennifer focused on private equity deals. She has also had diverse operational and research experience at companies such as Chiron, Genelabs, and Genencor. Jennifer brings over ten years of business development, portfolio management, and consulting experience as well as a biotechnology background to the team. She graduated magna cum laude with a BSE in Bioengineering and a Master's of Biotechnology from the University of Pennsylvania. Jennifer was also named a Joseph Wharton Fellow while completing her MBA at the Wharton school. In her free time Jennifer enjoys remaining involved with SpringBoard Enterprises as well as spending time with her husband and their twin children who keep them on their toes!
Sir Mike Gregory
Professor Sir Mike Gregory is Head of the Manufacturing and Management Division of the University Engineering Department and of the Institute for Manufacturing (IfM). Following an early career in industry he was the founder member of the team which established the Manufacturing Engineering Tripos, a senior undergraduate programme covering, marketing, design, production, distribution and service with very close industrial engagement. Subsequent developments in research and collaboration with industry reflected this broad view of manufacturing and led to the establishment of the IfM in 1998. Linking science, engineering, management and economics and integrating education, research and practice the IfM now has over 230 staff and research students and a further 100 undergraduate and Masters students.
Christopher S. Hayter
Chris Hayter is Assistant Professor at Arizona State University (ASU). Prior to joining the faculty at ASU, Chris served as Executive Director of the Policy Evaluation and Transformation Group at the New York Academy of Sciences where he led the Academy’s work in program evaluation, higher education and science policy, organizational restructuring and strategic planning, and entrepreneurship research. Chris has nearly fifteen years of experience managing complex science and innovation policy projects at organizations such as National Governors Association, Council on Competitiveness, National Academies’ Board on Science, Technology, and Economic Policy (STEP). He also worked for five years in the private sector establishing and managing new resort ventures for a large hospitality company. Prior to joining the Academy, he also served as Visiting Lecturer of Public Policy at the U.S. Coast Guard Academy.
Gregory Scott Horowitt
Greg is the co-founder and Managing Director of T2 Venture Creation, a multi-disciplinary venture capital and ecosystem advisory firm focused on building high impact technology and healthcare enterprises and the communities that support them. For more than a decade, Greg has been one of the world’s leading architects of regional and national economic development systems and has designed and / or been involved with the ecosystem architecture of more than 20 countries, communities, and companies globally. Today, he is recognized as one of the world’s top experts in the field and has been labeled the ‘Guru of Innovation’ by some of the world’s top publications and newspapers. This has led to advisory and speaking engagements with organizations including the Aspen Institute, World Bank, Inter-American Development Bank, US State Department, and National Academies of Science.
Karin Immergluck began working in university technology transfer fourteen years ago, managing a large portfolio of inventions on behalf of the entire University of California system at the Office of the President. In 2004, she joined the UCSF Office of Technology Management, and currently serves as Director, Technology Management, in the UCSF Office of Innovation, Technology and Alliances. In addition to directing the Technology Management team, she structures and negotiates large industry-university research alliances, supports UCSF faculty start-up entrepreneurs, and handles IP legal disputes and settlements. Under Karin's leadership, UCSF has become a pioneering leader within the university community in digital health licensing, and UCSF's licensing productivity has seen a 48% increase. Karin teaches several IP-related classes at UCSF and has served as an adviser to several government and academic institutions in Europe.
Sara Kenkare-Mitra PhD is currently Senior Vice President of Development Sciences, a translational sciences organization that spans R&D at Genentech. In this role she has responsibility for ensuring the successful translation of promising molecule-discoveries from Research into Development. Sara has had a significant impact on the development of a number of biologics and small molecules leading to Genentech's key product approvals including Avastin, Tarceva, Lucentis, Xolair, Erivedge, Perjeta and Kadcyla. In addition, more than 50 Investigational New Drug applications with potential to treat a multitude of diseases in particular cancer, have been filed by her organization with US and ex-US regulatory agencies. At Genentech she is a key member of the technical and portfolio decision-making committees.
Ravi Kiron is Managing Partner at BioPharma Strategy Advisors, Inc. and works across global pharma, biotech, diagnostics, medical device companies, providing value added R&D strategy, asset repositioning, investor funding, sales/ marketing connectivity, business development, IP and M&A due diligence. He is currently Entrepreneur in Residence (EIR) at SRI International, shepherding commercialization options for SRI inventions in biosciences and medical devices/ diagnostics, working with Dept. of Homeland Security & BARDA, and also consults for Private Equity & Hedge Funds in US/EU & Asia. Recently as CBO at Kinemed, he established pharma, biotech, and foundation partnerships for biomarker diagnostics. He was also Cofounder & CEO/CBO of Navya Biomed Tech, C2N Diagnostics; COO at Life Tech Innovations; Managing Director at Adjuvant Global Advisors & LifeTech Research. With over 28 years of industry experience at Academia (Cornell University), Pharma (Pfizer and J&J), Biotech (e.g. Numerate, Aduro); Ravi is well versed in drug discovery, drug delivery, pre-clinical drug development; bioinformatics, databases and corporate development and strategy.
Shilpi Mathrani, is currently a Master of Engineering in Bioengineering student at UC Berkeley. Shilpi also completed her undergraduate studies at UC Berkeley, majoring in bioengineering. She participated in the Biomanufacturing to Market program for two summers and is now on her fourth semester. Shilpi works with a start-up company called Mango Materials where they produce bio-plastic by feeding waste methane gas to bacteria.
Carol Mimura, Ph.D., RTTP is the Assistant Vice Chancellor for Intellectual Property & Industry Research Alliances (IPIRA) at U.C. Berkeley. IPIRA is the portal to Berkeley for industry access to Berkeley’s preeminent faculty and research capabilities. Carol established IPIRA with a talented team in 2004 and since that time, Berkeley has increased industry expenditures ~8-fold, to ~$86M annually. >825 companies sponsor research at U.C. Berkeley. She led the negotiation of a $500M agreement with BP on Energy Biosciences and oversees an office whose licensees have commercialized over 100 products to date, returning over $200M to Berkeley and its inventors in royalties. Over 150 startups have been founded to commercialize IP rights under license from U.C. Berkeley that create jobs, stimulate the economy, and actively participate in the Bay Area innovation ecosystem.
Janet Napolitano leads a university system with 10 campuses, five medical centers, three affiliated national laboratories, and a statewide agriculture and natural resources program. She is a distinguished public servant with a record of leading large, complex organizations at the federal and state levels. She served as Secretary of Homeland Security from 2009-13, as Governor of Arizona from 2003-09, as Attorney General of Arizona from 1998-2003, and as U.S. Attorney for the District of Arizona from 1993-97. Before that, she practiced at the law firm of Lewis & Roca in Phoenix, where she became a partner in 1989. She began her career in 1983 as a clerk for Judge Mary M. Schroeder of the U.S. Court of Appeals for the Ninth Circuit. As Governor of Arizona, Napolitano focused on education, from pre-kindergarten through public higher education. She was the first woman to chair the National Governors Association, and was named one of the nation’s top five governors by Time magazine. Napolitano earned a B.S. degree (summa cum laude in Political Science) in 1979 from Santa Clara University, where she was Phi Beta Kappa, a Truman Scholar and the university’s first female valedictorian. She received her law degree in 1983 from the University of Virginia School of Law. Napolitano holds honorary degrees from several universities and colleges, including Emory University, Pomona College and Northeastern University. In 2010, she was awarded the prestigious Thomas Jefferson Foundation Medal (Law), the University of Virginia’s highest external honor.
Dr. Ryan is the Chair of The Bay Area BioEconomy Initiative (BA-BI), a non-profit organization committed to fostering an atmosphere of innovation and collaboration in an effort to enhance a vibrant BioEconomy in the Bay Area. Dr. Ryan is Managing Director Golden Seeds (Silicon Valley), an investment firm that pursues above market returns through the empowerment of women entrepreneurs. She is also a partner in Astia Angel, investing in women-led ventures. She has a portfolio of over 25 startups in the Bay Area. Dr. Ryan was President and CEO of Diagnostics For All, Inc. (DFA), developing inexpensive diagnostics for global health and agriculture, and was President and CEO of Waltham Technologies, Inc. a cleantech/energy start-up. She was also formerly President and CEO of AVANT Immunotherapeutics, Inc., a company developing vaccines and immunotherapeutics for cancer, travelers, food safety, and global health. Dr. Ryan holds a Ph.D. in Cellular and Molecular Biology from Cambridge University and BS degrees in Zoology, Microbiology and Chemistry from Bristol University. She received an Honorary Doctor of Science degree from Bristol University in 2009. In 2007, Dr. Ryan received the Albert Einstein Award for outstanding achievement in the life sciences. In 2002 Her Majesty Queen Elizabeth II awarded Dr. Ryan the Order of the British Empire (OBE) for services to biotechnology.
Phil Sanderson is a team leader and project manager with the Therapeutics for Rare and Neglected Disease (TRND) program in the NIH’s Center for Advancing Translational Sciences. TRND stimulates drug discovery and development research collaborations among NIH and academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies working on rare and neglected illnesses. TRND has an experienced R&D staff and provides collaborators with in kind support for their projects. Prior to joining TRND, Phil was a team leader in Merck Research Laboratories where he led discovery and early development teams. Phil worked on a broad range of therapeutic targets and indications from new lead identification to the start of mid-stage clinical trials. Prior to joining Merck Phil was a Post-Doctoral Research Associate at Columbia University. He graduated and received his PhD from Cambridge University.
As the VP of Methane Marketing at Mango Materials, Anne Schauer-Gimenez fosters relationships with methane producing partners and also leads marketing and outreach efforts for the production of biodegradable plastics from waste biogas (methane). She also coordinates the UC-Berkeley interns through the Bio-manufacturing to Market program, which Mango Materials has been involved with for almost 2 years. Mango Materials, a small, local biotech start-up company, won the Postcode Lottery Green Challenge and received the “Excellence in the Field of Technology Research” award at CleanEquity Monaco. Mango Materials is currently focused on technology scale-up at sites of methane production. Anne has a BS in Environmental Science & MS in Environmental Science and Policy from the University of Wisconsin - Green Bay, along with a PhD in Civil Engineering from Marquette University (Milwaukee, WI). Her PhD research focused on using microorganisms to enhance anaerobic digestion.
Bill Shelander is the Commercialization Expert for Lawrence Berkeley National Laboratory. Since 2010, he has been working with researchers in fundamental energy technologies to commercialize new applications from biofuels and energy efficient building materials to life sciences, big data, and advanced imaging technologies. He has managed a small translational fund that has catalyzed newly licensed technologies and start ups. Previously Bill was a chemical engineer, national product manager, venture capitalist, and start up entrepreneur. He holds degrees from Stanford, West Virginia, and Georgia Tech.
Gregory Theyel is the Program Director for the East Bay Biomedical Manufacturing Network and Manufacturing Advisor for the Tech Futures Group. He has worked for over 15 years with large and small biomedical and energy technology companies assisting with business, technology, and production planning. Gregory focuses on technology review and assessment, bill of materials and supply chain development, technology transfer, prototype development and pilot testing. Gregory earned a doctorate from Clark University, has published widely in operations, management, and technology journals, and teaches courses in industrial engineering, technology management, and business strategy.
Vanessa Tolosa is a principal investigator (PI) in the Materials Engineering Division at Lawrence Livermore National Laboratory (LLNL). Her research focuses on the development of long-term implantable neural interfaces and biochemical microsensors for therapeutic applications in humans and for investigational platforms for scientific discovery. Vanessa is a member of the neurotech team at LLNL; The team was instrumental in the development of the world’s first commercial retinal prosthesis (artificialretina.energy.gov). The team has also been awarded two Defense Advanced Research Project Agency (DARPA) grants to develop the next-generation brain implants to treat neuropsychological illnesses brought on by traumatic experiences and to restore memory after injury or illness. These programs support President Obama’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN) initiative. As part of a dynamic program at a national lab, Vanessa integrates engineering, basic science, and clinical applications through partnerships with industry, academia, and research institutes. She holds a Ph.D. in Chemical Engineering from the University of California, Los Angeles.
Ramesh C. Trivedi
Ramesh Trivedi, Ph.D. (Chemical Engineering) and MBA is a member of the Life Science Angels group, which is ranked number one among over 350 other angel investment groups in the USA. Ramesh actively invests in Medical Technology and Biotech-Pharma Domains. Ramesh is a seasoned senior executive with 30+ years of experience as Director, CEO and President of early stage Private through Public corporations. Each of these companies developed disruptive technologies and commercial products such as, for example, the world’s very first autonomous Orthopedic and Neurosurgical robotic systems. He has done a capital raise of over $100 million from public and private, domestic and international investors as well as from strategics. He has licensed technologies from Universities and leveraged them to build successful commercial products and businesses. Ramesh is also the President of a medical device and international Consulting firm. He is also involved in assisting and mentoring early stage companies emerging from the local Universities and other academic institutions. Besides capital funding, Life Science Angels offer early stage companies, academic entrepreneurs and institutions much needed management and organizational skills. LSA also brings a large network of people and resources that would increase significantly the probability of success of these early stage companies. In the entrepreneurial Bay Area environment where time is very critical, association with Life Science Angels often enables early stage companies reach their milestones in a very timely manner.
Vivek Wadhwa is a Fellow at Arthur & Toni Rembe Rock Center for Corporate Governance, Stanford University; Director of Research at the Center for Entrepreneurship and Research Commercialization at the Pratt School of Engineering, Duke University; and Distinguished Fellow at Singularity University. He is author of “The Immigrant Exodus: Why America Is Losing the Global Race to Capture Entrepreneurial Talent”–which was named by The Economist as a Book of the Year of 2012. He was named by Foreign Policy Magazine as Top 100 Global Thinker in 2012. In 2013, TIME Magazine listed him as one of The 40 Most Influential Minds in Tech. Wadhwa oversees research at Singularity University, which educates a select group of leaders about the exponentially advancing technologies that are soon going to change our world. These advances—in fields such as robotics, A.I., computing, synthetic biology, 3D printing, medicine, and nanomaterials—are making it possible for small teams to do what was once possible only for governments and large corporations to do: solve the grand challenges in education, water, food, shelter, health, and security.
Randy Williams founded Keiretsu Forum in September 2000 to provide a disciplined and structured approach to angel investing. Mr. Williams’s passion for investing and bringing together like-minded community leaders has created a powerful and giving environment for entrepreneurs. With over 1,100 angel investor members throughout 34 chapters on 3 continents Keiretsu Forum is the largest angel investment community in the World. Mr. Williams is also the founder of the Keiretsu Forum Charitable Foundation. Since its inception in 2001, 114 deserving charities have been granted sizable donations. The goal of the Keiretsu Forum Charitable Foundation is to grant $250,000 annually, to worthy local charities throughout the Keiretsu Forum regional chapters.
Russ has been working for Operations in the medical device industry since 2004. He has participated in supporting production of commercial product and launching new products in both US and European markets. His primary interests include compliance to GMP,FDA and ISO regulations, analyzing process standards and machine utilization and working with HR on personnel career development for his team. He is currently a manager at Penumbra Inc, a privately held company, focused on treating stroke and vascular disease.